Central Nervous System

This course provides an overview of the best CNS presentations from the following abstracts:

  • Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial
  • A phase 2 study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with concomitant and adjuvant Metformin and Temozolomide (TMZ) in patients with Glioblastoma
  • Stereotactic radiosurgery versus whole-brain radiation therapy for patients with 4-15 brain metastases: A phase III randomized controlled trial
  • Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001
  • Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib
  • Timing of Adjuvant Radiotherapy in Atypical Meningiomas
  • Prospective Evaluation of Microscopic Extension using Macropathology in Glioma Patients: Determination of Optimal Clinical Target Volume Margins for Radiotherapy
  • Biomarkers of Post-radiation Cerebellar Injury Are Associated with Neurocognitive Decline in Primary Brain Tumor Patients

Target Audience

The course is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, surgeons, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, radiation dosimetrists, and all other health professionals involved in the field of radiation oncology.

Learning Objectives

Upon completion of this activity, learners should be able to do the following:

  • Evaluate novel studies in the management of glioblastoma with respect to dose escalation, neoadjuvant Metformin, and target volume design based on microscopic tumor extension.
  • Recognize differences in treatment strategies for multiple (4-15) brain metastases and BM in EGFR-mutant NSCLC.
  • Demonstrate an understanding of optimal timing of adjuvant RT in meningioma and the role of the cerebellum in post-RT neurocognitive decline.
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.
Course opens: 
01/01/2021
Course expires: 
12/31/2023
Cost:
$0.00
Part of: 
2020 Best of ASTRO onDemand
Rating: 
0

Central Nervous System
Jona Hattangadi-Gluth, MD is employed by University of California and has no other disclosures to declare.


The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
    The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  • 1.00 Certificate of Attendance
    This activity was designated for 1.00 AMA PRA Category 1 Credit™.

Price

Cost:
$0.00
Please login or register to take this course.